Dr. Quon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
403 W. Adams Blvd.
Los Angeles, CA 90007Phone+1 213-742-1000Fax+1 213-742-1000- Is this information wrong?
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2003- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1996 - 1999
David Geffen School of Medicine at UCLAClass of 1996
Certifications & Licensure
CA State Medical License 1998 - 2025- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Top Doctors:LA Area Castle Connolly, 2013
- Top Doctors:Southern California Castle Connolly, 2012
Clinical Trials
- Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A Start of enrollment: 2013 Mar 01
- Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B Start of enrollment: 2013 Feb 11
- Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- 5 citationsA Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.Glenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, Fabricio Racca, Doris Quon, Serge Leyvraz, Dagmar Hess, Bhumsuk Keam, Jordi Rodon, Myung-Ju Ahn, Hye Ryun Kim, ...> ;Cancer Research Communications. 2023 Sep 14
- 2 citationsA Phase I/II Investigation of Safety and Efficacy of Nivolumab and-Sirolimus in Patients With a Variety of Tumors With Genetic Mutations in the mTOR Pathway.Erlinda M Gordon, Nicole L Angel, Nadezhda Omelchenko, Victoria S Chua-Alcala, Ania Moradkhani, Doris Quon, Steven Wong> ;Anticancer Research. 2023 May 1
- 24 citationsTwo-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.Johnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, Susan Shapiro, Sheng-Chieh Chou, Margareth C Ozelo, Gili Kenet, Flora Peyvandi, Michael Wang, Bella Madan, ...> ;The New England Journal of Medicine. 2023 Feb 23
- Join now to see all
Journal Articles
- BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia ADoris V Quon, Margaret V Ragni, The New England Journal of Medicine
- Development and Reliability of the Joint Tissue Activity and Damage Examination for Quantitation of Structural Abnormalities by Musculoskeletal Ultrasound in Hemophili...Eric Y Chang, Annette von Drygalski, Doris V Quon, Tudor H Hughes, Journal of Ultrasound in Medicine
Press Mentions
BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia AJanuary 2nd, 2020
Clinical Challenge: From Pediatric to Adult Hemophilia CareDecember 17th, 2019
California's Most Expensive Patient in Recent Years Has HemophiliaMarch 6th, 2018
Hospital Affiliations
Cedars-Sinai Medical CenterLos Angeles, California
Keck Hospital of USCLos Angeles, California
Ronald Reagan UCLA Medical CenterLos Angeles, California
Providence Saint John's Health CenterSanta Monica, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
